Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 6/20 | 0.44 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.36 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.36 |
| ▸ | EEF2K | O00418 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | CLK2 | P49760 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | PRKX | P51817 | 1/20 | 0.35 |
| ▸ | NEK4 | P51957 | 1/20 | 0.35 |
| ▸ | PRKG2 | Q13237 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.35 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.35 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.35 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.35 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL660243 | 0.84 | MAP2K4 (0.45) | NR1H2MAP2K4PDGFRACDK5TYRO3 | |
| SCHEMBL13748554 | 0.83 | MAP2K4 (0.44) | NR1H2MAP2K4PDGFRACDK5TYRO3 | |
| SCHEMBL1943689 | 0.82 | PDGFRA (0.52) | MAP2K4PDGFRACDK5TYRO3GSK3B | |
| SCHEMBL29439761 | 0.82 | PDGFRA (0.52) | MAP2K4PDGFRACDK5TYRO3GSK3B | |
| SCHEMBL16800567 | 0.82 | MAP2K4 (0.46) | MAP2K4PDGFRACDK5TYRO3SMARCA2 | |
| SCHEMBL4035945 | 0.81 | NR1H2 (0.38) | NR1H2MAP2K4PDGFRACDK5TYRO3 | |
| SCHEMBL16800427 | 0.80 | MAP2K4 (0.62) | MAP2K4PDGFRACDK5TYRO3SMARCA2 | |
| SCHEMBL15081343 | 0.80 | MAP2K4 (0.42) | NR1H2MAP2K4PDGFRACDK5TYRO3 | |
| SCHEMBL18108772 | 0.79 | MAP2K4 (0.44) | MAP2K4KDM4E | |
| SCHEMBL922232 | 0.79 | MAP2K4 (0.41) | NR1H2MAP2K4PDGFRACDK5TYRO3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872039-B2 | N-3-chlorobenzyl-3-amino-1H-indazole-5-carboxamide; 3-aminoindazoles; glucocorticoid-depedent kinase (SGK) inhibitors; SGK-induced diseases; diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and renal diseases, fibrosis; inflammatory agents | MERCK PATENT GESELLSCHAFT (DE) | 2011-01-18 | — | — | US | disclosed |
| US-7872039-B2 | N-3-chlorobenzyl-3-amino-1H-indazole-5-carboxamide; 3-aminoindazoles; glucocorticoid-depedent kinase (SGK) inhibitors; SGK-induced diseases; diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and renal diseases, fibrosis; inflammatory agents | MERCK PATENT GESELLSCHAFT (DE) | 2011-01-18 | — | — | US | disclosed |
| US-7872039-B2 | N-3-chlorobenzyl-3-amino-1H-indazole-5-carboxamide; 3-aminoindazoles; glucocorticoid-depedent kinase (SGK) inhibitors; SGK-induced diseases; diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and renal diseases, fibrosis; inflammatory agents | MERCK PATENT GESELLSCHAFT (DE) | 2011-01-18 | — | — | US | disclosed |
| EP-1765788-B1 | 3-AMINOINDAZOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SGK-ASSOCIATED DISEASES | MERCK PATENT GMBH (DE) | 2009-06-03 | — | — | EP | disclosed |
| US-20070232620-A1 | 3-Aminoindazoles | MERCK PATENT GMBH (DE) | 2007-10-04 | — | — | US | disclosed |
| US-20070232620-A1 | 3-Aminoindazoles | MERCK PATENT GMBH (DE) | 2007-10-04 | — | — | US | disclosed |
| US-20070232620-A1 | 3-Aminoindazoles | MERCK PATENT GMBH (DE) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232620-A1 | 3-Aminoindazoles | SGK3, SGK1, SGK2 | NR1H2 741/4885MAP2K4 633/4885PDGFRA 2520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.